Lenalidomide
Payments companies reported to CMS as associated with Lenalidomide. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lenalidomide, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lenalidomide
These are the largest totals companies reported as associated with Lenalidomide. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Elias Jabbour | Houston, TX | Hematology & Oncology | $23,787.41 |
| Hagop Kantarjian | Houston, TX | Medical Oncology | $19,809.60 |
| Nuhad Ibrahim | Houston, TX | Medical Oncology | $16,001.61 |
| Nitin Jain | Houston, TX | Internal Medicine | $14,127.61 |
| Naval Daver | Houston, TX | Hematology & Oncology | $13,419.81 |
| Vamsidhar Velcheti | Jacksonville, FL | Hematology & Oncology | $13,361.52 |
| Tapan Kadia | Houston, TX | Internal Medicine | $12,724.61 |
| Rami Komrokji | Tampa, FL | Hematology (Internal Medicine) | $11,777.91 |
| Joseph Mikhael | Scottsdale, AZ | Hematology (Internal Medicine) | $1,000.00 |
Prescribed Lenalidomide?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.